Acepodia, Inc.
TTPEX:697613.35
TWD
+0.10
(+0.75%)
ISIN
KYG0073G1091
CUSIP
G0073G109
Return %
Stock
S&P 500
1Y
-20.06
14.20
3Y
-59.05
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Sonny Hsiao
- Full Time Employees
- 105
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Ugland House New Taipei TP Taiwan KY1-1104
- IPO Date
- Aug 8, 2023
- Website
- acepodia.com
- Similar Companies
- Business
- Acepodia, Inc. (6976.TWO) is a clinical-stage biotechnology company that develops innovative off-the-shelf allogeneic cell therapies for oncology and autoimmune diseases using its proprietary Antibody-Cell Conjugation (ACC) platform technology, which attaches tumor-targeting antibodies to immune cells such as gamma delta 2 T cells and off-the-shelf natural killer (oNK) cells without genetic engineering; core product candidates include ACE1831 (CD20-targeting ACC-γδ2 T cell therapy for non-Hodgkin lymphoma and IgG4-related disease), ACE2016 (EGFR-targeting ACC-γδ2 T cell therapy for EGFR-positive solid tumors such as lung cancer), ACE1702 (HER2-targeting oNK cell therapy for HER2-positive solid tumors such as breast cancer), and ACE1708 (PD-L1-targeting γδ2 T cell therapy for solid tumors), alongside the Antibody-Dual-Drugs Conjugation (AD2C) platform targeting GPC3 for hepatocellular carcinoma (HCC). Founded in 2017 and headquartered in Grand Cayman, Cayman Islands, with key operations in Alameda, California, USA, and Taipei, Taiwan, the company targets hematologic cancers, solid tumors, and autoimmune conditions like IgG4-related disease through its gamma delta 2 T cell, oNK cell, and AD2C technologies. Recent developments include FDA clearance in November 2024 for a Phase 1b/2a trial of ACE1831 in IgG4-related disease with plans for multi-country IND approvals and Orphan Drug Designation by H1 2025, clinical protocol amendments for ACE1831 to enable multi-dose regimens by H1 2025, completion of double-digit patient enrollment in the ACE2016 Phase I trial for EGFR-positive solid tumors in 2025, preclinical initiation of AD2C anti-GPC3 for HCC in 2025, and a strategic clinical collaboration with Pfizer announced in September 2024 to accelerate development across oncology and autoimmune indications.